TroVax(®) vaccine therapy for renal cell carcinoma (Q37965748)

26 August 2017

title

TroVax(®) vaccine therapy for renal cell carcinoma (English)

1 reference

26 August 2017

4

Howard L Kaufman

1 reference

26 August 2017

Rui-Tao Zhang

1

1 reference

26 August 2017

Steven D Bines

series ordinal

2

1 reference

26 August 2017

Carl Ruby

series ordinal

3

1 reference

26 August 2017

publication date

1 January 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

4

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

27-42

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

26 August 2017

1 reference

Sex differences in renal cell cancer presentation and survival: an analysis of the National Cancer Database, 1993-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

von Hippel-Lindau disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Renal cell carcinoma and occupational exposure to chemicals in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Renal cell cancer stage migration: analysis of the National Cancer Data Base

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Chemotherapeutic strategies for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Cancer immunoediting from immune surveillance to immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Antigen-specific immunotherapy and cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

T(H)17 cells in tumour immunity and immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

B cells inhibit induction of T cell-dependent tumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

A history of prostate cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Interleukin-2-dependent mechanisms of tolerance and immunity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Transient T cell depletion causes regression of melanoma metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Immunohistological distribution of 5T4 antigen in normal and malignant tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

A 72 kD trophoblast glycoprotein defined by a monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

CD8 T-cell recognition of human 5T4 oncofetal antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Pox viral vaccine approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Combined modality immunotherapy and chemotherapy: a new perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Improved Endpoints for Cancer Immunotherapy Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

The PD-1 pathway in tolerance and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Toll-like receptors on tumor cells facilitate evasion of immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

A Prospective Study of Body Mass Index, Hypertension, and Smoking and the Risk of Renal Cell Carcinoma (United States)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Identification of a tumor-initiating stem cell population in human renal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

Microvesicles Released from Human Renal Cancer Stem Cells Stimulate Angiogenesis and Formation of Lung Premetastatic Niche

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.160

21 January 2018

Identifiers

DOI

10.2217/IMT.11.160

1 reference

26 August 2017

1 reference